A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED)
Merck Sharp & Dohme Corp.
The primary purpose of this study is to investigate the contraceptive efficacy, safety and
acceptability of Organon's subdermal etonogestrel implant in healthy female volunteers in
various countries in order to obtain country-specific data.
Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
University of Utah
A highly effective single rod contraceptive implant is now available for use in the US.
Delays in the insertion of the device until later in the postpartum period may negatively
impact initiation rates. The objective of this study is to compare outcomes of early
postpartum insertion (prior to postpartum hospital discharge) of the etonogestrel-releasing
contraceptive implant with routine postpartum insertion at 4-8 weeks after delivery. Primary
outcome of interest will be time to lactogenesis. Secondary outcomes will include rates of
breastfeeding supplementation, infant growth, vaginal bleeding patterns, incidence of side
effects, time to resume sexual intercourse after delivery, and incidence of missed routine
postpartum follow-up. In addition, a subset of patients who randomize to early postpartum
insertion will have expressed breastmilk ascertained for nutrient composition.
Acceptability of Long-term Progestin-only Contraception in Europe
The study examines the use of Mirena or Implanon for long-term contraception in women. The
duration of therapy use is the key focus of the study. Also, any reasons for discontinuation
and the safety profile will be examined. In addition, patients are asked to fill out a short
questionnaire about their menstrual bleeding before and during therapy.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.